Product Program year 2025 Source: CMS Open Payments

Fycompa

Drug Neurology

NDC 62856-272-30

Open in the dashboard

General payments

$4,689,775

44,323 payments

Research payments

$8,522,480

1,483 payments

Through program year 2025, $4,689,775 in general payments and $8,522,480 in research payments were reported against Fycompa (Neurology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

13 rows
Year Kind Amount Payments
2025 Research $206,559 21
2024 General $16,978 10
2024 Research $274,473 41
2023 General $111,677 2,539
2023 Research $846,347 117
2022 General $551,007 12,072
2022 Research $758,134 111
2021 General $617,890 11,412
2021 Research $2,097,717 411
2020 General $841,389 5,878
2020 Research $1,955,382 291
2019 General $2,550,834 12,412
2019 Research $2,383,869 491

Breakdown

Who paid General payments · program years 2019–2024
  1. Eisai Inc. $4,633,839 44,297 payments
  2. Eisai Co., Ltd. $55,936 26 payments
Top recipients General payments · program year 2024
  1. Vineet Punia Neurology · Cleveland Heights, OH $8,538 50% · 6 payments
  2. Aatif Husain Neurology · Durham, NC $4,930 29% · 2 payments
  3. Gregory Holmes Neurology with Special Qualifications in Child Neurology · Burlington, VT $2,700 16% · 1 payment
  4. Alexa Craig Neurology with Special Qualifications in Child Neurology · Scarborough, ME $810 5% · 1 payment

Each share is of general payments naming this product in 2024.

Specialties paid General payments · program year 2024
  1. Neurology Psychiatry & Neurology $13,468 79% · 2 practitioners
  2. Neurology with Special Qualifications in Child Neurology Psychiatry & Neurology $3,510 21% · 2 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. Ohio $8,538 50% · 1 recipient
  2. North Carolina $4,930 29% · 1 recipient
  3. Vermont $2,700 16% · 1 recipient
  4. Maine $810 5% · 1 recipient

Each share is of general payments naming this product in 2024 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

47,067

Prescriptions dispensed, refills included

Drug cost

$58,814,269

Paid at the pharmacy, in all

Prescribers

1,789

With 11 or more claims of it

Medicare Part D drugs matched to Fycompa, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Fycompa Perampanel Same name 1,789 47,067 $58,814,269

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jessica Bishop Physician Assistant ID 374 $474,163 $2,346
Misha Kucherov Neurology NY 258 $283,600 $79
Ricardo Ayala Pediatric Medicine FL 194 $253,566 $130
Kelly Langenbeck Nurse Practitioner OH 181 $238,102 $181
Charles Ugokwe Neurology LA 179 $210,157 $39

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
44,323 general · 1,483 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record